<h2>关键点</h2>
<ul>
<li>在他看来，现在只是持有。</li>
<li>该分析师还将他的目标价下调了近一半。</li>
<li>我们更看好的 10 只股票超过 Phreesia ›</li>
</ul>
<p>医疗科技股 <strong>Phreesia</strong>(NYSE: PHR) 在周三可能需要一些提振。在一个以正面收尾的交易时段中，基准 <strong>S&amp;P 500</strong> 指数上涨超过 1%，而 Phreesia 的股价却下跌了 3.5%。这在很大程度上是由于一位分析师的评级下调所致。</p>
<h2>因评级下调而受损</h2>
<p>负责此事的是美国四大银行之一的 <strong>Wells Fargo</strong> 的 Stan Berenshteyn。当天早上，他将对 Phreesia 的评级从之前的超配（买入）调整为等权重（持有）。同时，他还大幅下调了目标价，从 15 美元降至每股 9 美元。</p>
<p><em><strong>人工智能会创造出世界首位万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg3MTE3MC9oZWFsdGhjYXJlLXByb2Zlc3Npb25hbC1pbnNwZWN0aW5nLWNoYXJ0cy5qcGcmdz03MDA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg3MTE3MC9oZWFsdGhjYXJlLXByb2Zlc3Npb25hbC1pbnNwZWN0aW5nLWNoYXJ0cy5qcGcmdz03MDA"/></p>
<p>图片来源：Getty Images。</p>
<p>根据报道，这位分析师在对医疗科技公司的产品进行渠道检查后做出了这一决定。他写道，这些检查表明竞争日益加剧，导致他下调了对至关重要的订阅收入的预期。</p>
<p>Berenshteyn 补充说，他的研究表明，患者接收软件比工作流程软件更容易被替代，因此更容易受到竞争解决方案的影响。在他看来，这使得 Phreesia 处于脆弱状态。</p>
<h2>该股票现在被低估了吗？</h2>
<p>Wells Fargo 的预测者指出的另一个负面因素是 Phreesia 客户的一般特征。他写道，该公司的优势在于私人执业者，而这一细分市场正受到越来越多小型开发商等竞争对手的瞄准。</p>
<p>虽然 Berenshteyn 在他的更新中提出了一些合理的观点，但我个人并不准备放弃 Phreesia。</p>
<p>尽管最近下调了年度收入指引，导致股价跌至历史低点，但该公司在其业务中正变得越来越成熟，医疗科技领域的客户通常会坚持使用同一供应商（从而避免向新供应商的破坏性转变）。我对该股的看法比分析师更乐观；在我看来，它的股票仍然看起来值得买入。</p>
<h2>你现在应该购买 Phreesia 的股票吗？</h2>
<p>在你购买 Phreesia 的股票之前，请考虑以下几点：</p>
<p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买……而 Phreesia 并不在其中。入选的 10 只股票在未来几年可能会产生巨额回报。</p>
<p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 481,750 美元</strong>！* 或者当 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 1,352,457 美元</strong>！*</p>
<p>现在，值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 990%——相比之下，S&amp;P 500 的回报率为 206%。<strong>不要错过最新的前 10 名单，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em>。</strong></p>
<p><strong>查看这 10 只股票 »</strong></p>
<p><em>*Stock Advisor 的回报截至 2026 年 5 月 20 日。</em></p>
<p><em>Wells Fargo 是 Motley Fool Money 的广告合作伙伴。Eric Volkman 在提到的任何股票中没有持仓。Motley Fool 在提到的任何股票中没有持仓。Motley Fool 有披露政策。</em></p>
<p>此处表达的观点和意见是作者的观点和意见，并不一定反映 Nasdaq, Inc.的观点。</p>

<p>Phreesia（纽约证券交易所代码：PHR）股票在市场整体向好的情况下仍下跌了 3.5%，原因是富国银行分析师 Stan Berenshteyn 将其评级下调至 “持有”，并将目标价从 15 美元下调至 9 美元。此次下调的原因归因于竞争加剧以及对订阅收入的担忧。虽然 Berenshteyn 强调了 Phreesia 客户基础的脆弱性，但一些分析师对该公司的长期前景仍持乐观态度</p>

<h2>Key Points</h2>
<div class="lb-trans"><h2>关键点</h2>
</div><ul>
<li>In his view, it's only a hold now.</li>
<li>The pundit also reduced his price target by nearly half.</li>
<li>10 stocks we like better than Phreesia ›</li>
</ul>
<div class="lb-trans"><ul>
<li>在他看来，现在只是持有。</li>
<li>该分析师还将他的目标价下调了近一半。</li>
<li>我们更看好的 10 只股票超过 Phreesia ›</li>
</ul>
</div><p>Healthcare tech stock <strong>Phreesia</strong>(NYSE: PHR) could have used a pick-me-up on Wednesday. In a trading session that ended in positive territory, with the bellwether <strong>S&amp;P 500</strong> index gaining more than 1%, Phreesia's equity lost 3.5% of its value. Much of this was directly due to an analyst's recommendation downgrade.</p>
<div class="lb-trans"><p>医疗科技股 <strong>Phreesia</strong>(NYSE: PHR) 在周三可能需要一些提振。在一个以正面收尾的交易时段中，基准 <strong>S&amp;P 500</strong> 指数上涨超过 1%，而 Phreesia 的股价却下跌了 3.5%。这在很大程度上是由于一位分析师的评级下调所致。</p>
</div><h2>Docked with a downgrade</h2>
<div class="lb-trans"><h2>因评级下调而受损</h2>
</div><p>The responsible party was Stan Berenshteyn of &#34;Big Four&#34; U.S. bank <strong>Wells Fargo</strong>. Early that morning, he changed his rating on Phreesia to equal weight (hold, in other words) from his preceding overweight (buy). Accompanying that was a significant price target modification, with Berenshteyn lowering his to $9 per share from $15.</p>
<div class="lb-trans"><p>负责此事的是美国四大银行之一的 <strong>Wells Fargo</strong> 的 Stan Berenshteyn。当天早上，他将对 Phreesia 的评级从之前的超配（买入）调整为等权重（持有）。同时，他还大幅下调了目标价，从 15 美元降至每股 9 美元。</p>
</div><p><em><strong>Will AI create the world's first trillionaire?</strong> Our team just released a report on the one little-known company, called an &#34;Indispensable Monopoly&#34; providing the critical technology Nvidia and Intel both need. <strong>Continue »</strong></em></p>
<div class="lb-trans"><p><em><strong>人工智能会创造出世界首位万亿富翁吗？</strong> 我们的团队刚刚发布了一份关于一家鲜为人知的公司报告，该公司被称为 “不可或缺的垄断”，提供 Nvidia 和 Intel 都需要的关键技术。<strong>继续 »</strong></em></p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-dXJsPWh0dHBzOi8vZy5mb29sY2RuLmNvbS9lZGl0b3JpYWwvaW1hZ2VzLzg3MTE3MC9oZWFsdGhjYXJlLXByb2Zlc3Npb25hbC1pbnNwZWN0aW5nLWNoYXJ0cy5qcGcmdz03MDA" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F871170%2Fhealthcare-professional-inspecting-charts.jpg&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><p>According to reports, the analyst made his move following channel checks on the healthcare tech company's offerings. He wrote that these indicated mounting competition, leading him to reduce his estimates for all-important subscription revenue.</p>
<div class="lb-trans"><p>根据报道，这位分析师在对医疗科技公司的产品进行渠道检查后做出了这一决定。他写道，这些检查表明竞争日益加剧，导致他下调了对至关重要的订阅收入的预期。</p>
</div><p>Berenshteyn added that his research indicated patient intake software is more replaceable -- and thus subject to competing solutions -- than workflow software. This, in his view, makes Phreesia vulnerable.</p>
<div class="lb-trans"><p>Berenshteyn 补充说，他的研究表明，患者接收软件比工作流程软件更容易被替代，因此更容易受到竞争解决方案的影响。在他看来，这使得 Phreesia 处于脆弱状态。</p>
</div><h2>Is the stock now underrated?</h2>
<div class="lb-trans"><h2>该股票现在被低估了吗？</h2>
</div><p>Another negative factor pointed out by the Wells Fargo prognosticator is the general profile of Phreesia's clients. He wrote that the company's strength is private practitioners, a segment being increasingly targeted by smaller developers, among other rivals.</p>
<div class="lb-trans"><p>Wells Fargo 的预测者指出的另一个负面因素是 Phreesia 客户的一般特征。他写道，该公司的优势在于私人执业者，而这一细分市场正受到越来越多小型开发商等竞争对手的瞄准。</p>
</div><p>While Berenshteyn makes some solid points in his update, I personally wouldn't be ready to throw in the towel on Phreesia.</p>
<div class="lb-trans"><p>虽然 Berenshteyn 在他的更新中提出了一些合理的观点，但我个人并不准备放弃 Phreesia。</p>
</div><p>Despite a recent cut to its annual revenue guidance that pushed the stock to historic lows, the company is becoming increasingly well-established in its business, and clients in the healthcare tech space often stick with the same vendor (thus avoiding disruptive shifts to new ones). I'm more bullish than the analyst; to me, its stock still looks like a buy.</p>
<div class="lb-trans"><p>尽管最近下调了年度收入指引，导致股价跌至历史低点，但该公司在其业务中正变得越来越成熟，医疗科技领域的客户通常会坚持使用同一供应商（从而避免向新供应商的破坏性转变）。我对该股的看法比分析师更乐观；在我看来，它的股票仍然看起来值得买入。</p>
</div><h2>Should you buy stock in Phreesia right now?</h2>
<div class="lb-trans"><h2>你现在应该购买 Phreesia 的股票吗？</h2>
</div><p>Before you buy stock in Phreesia, consider this:</p>
<div class="lb-trans"><p>在你购买 Phreesia 的股票之前，请考虑以下几点：</p>
</div><p>The <em>Motley Fool Stock Advisor</em> analyst team just identified what they believe are the <strong>10 best stocks</strong> for investors to buy now… and Phreesia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.</p>
<div class="lb-trans"><p><em>Motley Fool Stock Advisor</em> 分析师团队刚刚确定了他们认为的 <strong>10 只最佳股票</strong>，供投资者现在购买……而 Phreesia 并不在其中。入选的 10 只股票在未来几年可能会产生巨额回报。</p>
</div><p>Consider when <strong>Netflix</strong> made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, <strong>you’d have $481,750</strong>!* Or when <strong>Nvidia</strong> made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, <strong>you’d have $1,352,457</strong>!*</p>
<div class="lb-trans"><p>考虑一下 <strong>Netflix</strong> 在 2004 年 12 月 17 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 481,750 美元</strong>！* 或者当 <strong>Nvidia</strong> 在 2005 年 4 月 15 日进入这个名单时……如果你在我们推荐时投资了 1000 美元，<strong>你将拥有 1,352,457 美元</strong>！*</p>
</div><p>Now, it’s worth noting <em>Stock Advisor’s</em> total average return is 990% — a market-crushing outperformance compared to 206% for the S&amp;P 500. <strong>Don't miss the latest top 10 list, available with <em>Stock Advisor</em>, and join an investing community built by individual investors for individual investors.</strong></p>
<div class="lb-trans"><p>现在，值得注意的是 <em>Stock Advisor</em> 的总平均回报率为 990%——相比之下，S&amp;P 500 的回报率为 206%。<strong>不要错过最新的前 10 名单，加入由个人投资者为个人投资者建立的投资社区，获取 <em>Stock Advisor</em>。</strong></p>
</div><p><strong>See the 10 stocks »</strong></p>
<div class="lb-trans"><p><strong>查看这 10 只股票 »</strong></p>
</div><p><em>*Stock Advisor returns as of May 20, 2026.</em></p>
<div class="lb-trans"><p><em>*Stock Advisor 的回报截至 2026 年 5 月 20 日。</em></p>
</div><p><em>Wells Fargo is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.</em></p>
<div class="lb-trans"><p><em>Wells Fargo 是 Motley Fool Money 的广告合作伙伴。Eric Volkman 在提到的任何股票中没有持仓。Motley Fool 在提到的任何股票中没有持仓。Motley Fool 有披露政策。</em></p>
</div><p>The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.</p>
<div class="lb-trans"><p>此处表达的观点和意见是作者的观点和意见，并不一定反映 Nasdaq, Inc.的观点。</p>
</div>

为什么 Phreesia 的股票今天遭受重创